Pensacola 41 Fairpoint Drive Suite B Gulf Breeze, FL 32561

Boca Raton 9980 N Central Park Blvd Suite 202 Boca Raton, FL 33428





RKFMV

	<u>INFORMA</u>			
Name: Phone:		DOB:	· · · · · · · · · · · · · · · · · · ·	M 🗆 F 🗆
□NKDA Allergies:			Weight lbs/kg:	
PHYSICIAN	INFORM	ATION		
Physician Name:	Practice Nam	e:		
Address:	Office Contact Name: Office Contact #:			
Phone: Fax:	Email (for upo	dates):		
REFERRA	L STATUS			
□New Referral □Referral Renewal □Medication/Order Ch	ange □Ben	efits Verificatio	n Only □Discon	tinuation Order
MEDICATION ORDERS □ gMG who are anti-acetylcholine receptor (ArchR) antibody+ ICD 10:	□ atypical Hemolytic Uremic Syndrome (aHUS) ICD 10: aHus NEW START dosing (18 yo and older)* □ 900 mg weekly for the first 4 weeks, followed by			
gMG NEW START dosing (adult dosing) □ 900 mg weekly for the first 4 weeks, followed by □ 1,200 mg for the fifth dose 1 week later then □ 1,200 mg every 2 weeks x • Refills* □None □x6 months □x1year □Other: *(if not indicated order will expire one year from date signed	□ 1,200 mg for the fifth dose 1 week later then □ 1,200 mg every 2 weeks x ■ Refills* □None □x6 months □x1year □Other: ■ *(if not indicated order will expire one year from date signed PT wt and dosing Body WT Introduction Maintenance Maintena			
Paroxysmal Nocturnal Hemoglobinuria (PNH)	dosing	40kg and over	900mg weekly x 4 doses	1200mg at week 5 then
ICD 10:	□ WT	30kg to < 40kg	600mg weekly x 2 doses	1200mg every 2 weeks 900mg at week 3 then 900mg every 2 weeks
PNH BKEMV NEW START dosing (18 yo and older)	□ WT	20kg to < 30kg	600mg weekly x 2 doses	600mg at week 3 then 600mg every 2 weeks
□ 600 mg weekly for the first 4 weeks, followed by	□ WT	10kg to < 20kg	600mg weekly x 1 doses	300mg at week 2 then 300mg every 2 weeks
□ 900 mg for the fifth dose 1 week later then □ 900 mg every 2 weeks x	□ WT	5kg to <10kg	300mg weekly x 1 doses	300mg at week 2 then 300mg every 3 weeks
Refills* □None □x6 months □x1year □Other: *(if not indicated order will expire one year from date signed) **The state of the	***Complete or update vaccination from meningococcal bacteria (for serogroups A,C,W,Y, and B) at least 2 weeks prior to the first dose of BKEMV, unless the risks of delaying therapy with BKEMV outweigh the risk of developing a serious infection.Comply with the most current			
REQUIRED DOCUMENTATION CHECKLIST:	Advisory Committee on Immunization Practices (ACIP) recommendation for vaccinations against meningococcal bacteria in patients receiving a		P) recommendations atients receiving a	
□ This signed order form by the provider □ Patient demographics AND insurance information	complement inhibitor. See Warning and Precautions (5.1) for additional guidance on the management of the risk of serious infections caused by meningococcal bacteria.			
□ Clinical/ Progress notes supporting primary dx				
□ Acetylcholine Receptor Antibody Test Results (if Myasthenia Gravis)	WARNINGS AND PRECAUTIONS https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761333s001lbl.pdf			

ORDERING PROVIDER

□ WITH DATES OF ADMINISTRATION OF MEN ABCWY **OR**

□ IF NOT FULLY VACCINATED PROPHYLACTIC ANTIBX RM MUST BE SENT

 \square Is your patient enrolled in the BKEMV REMS program \square YES \square NO (If no, must be enrolled to start therapy)

□ Is the ordering PROVIDER enrolled in the BKEMV REMS program □YES □NO (If no, must be enrolled to start therapy)

Signature X		Date
Provider	Phone	Provider NPI